EAACI Congress 2025
BackOAS19 - Treatment response in severe asthma: from rehabilitation to biologic
Sunday 15 Jun, 17:30 PM -
19:00 PM Glasgow, United Kingdom
Carron 1
Oral Abstract Sessions
17:30
Sustained reduction in Severe Asthma Exacerbations and Hospitalisations in the 12 months after Alpine Altitude Climate Treatment
17:42
Registry on Severe Asthma with and without biological treatment in Spain: Results of a 2 year follow-up of AlergoDATA
17:54
Baseline Predictors of Multicomponent Clinical Remission Following Dupilumab Treatment in Patients With Moderate-to-Severe Asthma
18:06
Benralizumab reduces annual cumulative OCS dose while improving asthma control and quality of life in severe eosinophilic asthma: Real-World Evidence from the AURORA study
18:18
Assessing the Impact of Dupilumab Treatment on Lung Function in Patients With Chronic Obstructive Pulmonary Disease and Type 2 Inflammation
18:30
Twice-Yearly Depemokimab Efficacy is Sustained Across Seasons in Patients with Asthma: Analyses of Pooled Phase III SWIFT-1/2 Studies
18:42
Mepolizumab Improves and Sustains Asthma Control and Lung Function in Patients with Severe Asthma Independent of Baseline Blood Eosinophil Count in the Real World: Results from REALITI-A at 2 Years
